Clinical Trial

Safety and Durability of Sirolimus for Treatment of LAM

Study acronym: MIDAS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2015-05-01; most recent amendment 2024-12-18.
Status change: Active, Not Recruiting → Recruiting 2022-01-11
Status change: Recruiting → Active, Not Recruiting 2019-09-27
Trial Details
NCT Number NCT02432560
Lead Sponsor University of Cincinnati
Collaborators: Rare Diseases Clinical Research Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), The LAM Foundation
Conditions Lymphangioleiomyomatosis
Enrollment 600 participants
Start Date 2015-03
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-24